Researchers at Johns Hopkins report that a hormone used for bone disease may do more than strengthen bones: it could block the nerve invasion that causes chronic lower back pain. In animal tests, parathyroid hormone treatments thickened fragile vertebral end plates and triggered a bone cell signal that pushes pain-sensing nerves away. These findings point to a possible disease-modifying approach to spinal degeneration rather than only masking symptoms.
Chronic back pain often traces back to worn spinal discs and the thin end plates that separate discs from vertebrae, which can become porous with age or injury. When those barriers break down, nerves that normally avoid the spinal center can creep in and produce persistent discomfort. That basic biology makes the end plates and the cells around them a logical target for intervention.
The Johns Hopkins team focused on parathyroid hormone, commonly abbreviated PTH, which the body naturally makes to manage calcium and bone turnover. Synthetic forms of PTH are already prescribed to treat osteoporosis and are known to boost bone density. Clinicians had anecdotally noticed some patients on PTH reporting less back pain, and the lab work set out to explain why.
In controlled animal experiments, a one- to two-month course of PTH produced thicker, more resilient vertebral end plates in the spine. Those structural changes alone can reduce the routes through which nerves invade sensitive tissue. But the bigger surprise came from what the bone-building cells began to secrete.
Osteoblasts, the cells that lay down new bone, increased production of a protein called Slit3 when stimulated by PTH. The research shows Slit3 acts like a molecular repellent, discouraging growing nerve fibers from moving into areas they should not occupy. Removing Slit3 from the test animals erased the pain-relief effect, which strongly suggests that Slit3 is the key mediator.
“During spinal degeneration, pain-sensing nerves grow into regions where they normally do not exist. Our findings show that parathyroid hormone can reverse this process by activating natural signals that push these nerves away,” Crane said in a press release. That exact observation from the study underscores the mechanism: PTH does not just mask pain, it appears to redirect the biology that enables nerve encroachment.
Because PTH is already an approved therapy for osteoporosis, repurposing it for spine disease could be faster than developing a brand-new drug. Still, translating results from mice to people is never simple, and the timing, dosing, and long-term safety of PTH for spinal degeneration must be worked out. The idea would be to use an existing tool with a new goal: prevent abnormal innervation and stabilize spinal anatomy.
Investigators were careful to flag open questions. PTH can have systemic effects and might influence the central nervous system in ways that were not fully explored in the study. The experiment centered on Slit3, so it did not map every genetic pathway or bone-forming process that could matter in human spines.
“Our study suggests that PTH treatment of [lower back pain] during spinal degeneration may reduce aberrant innervation (abnormal nerve growth),” Crane concluded. That quote captures the potential clinical shift from treating symptoms to altering the disease process itself, while acknowledging this is an early, mechanistic result rather than final proof.
Next steps will likely include carefully designed clinical trials to test whether PTH can reduce pain and prevent nerve invasion in people with disc and end plate degeneration. Researchers will also need to check for unintended effects and identify which patients might benefit most. If the human studies confirm the animal work, clinicians could gain a powerful new tool to stop back pain at its source.
The study, which pinpoints a direct link between hormone-driven bone remodeling and nerve guidance, was published in the journal Bone Research. It opens a path for research into other factors that influence spinal nerve growth and for therapies that aim to repair structural damage rather than simply manage chronic pain.
